Cannabinoid CB
Animals
Behavior, Animal
/ drug effects
Cannabinoid Receptor Antagonists
/ pharmacology
Cocaine
/ adverse effects
Conditioning, Operant
/ drug effects
Depression
/ prevention & control
Drug-Seeking Behavior
/ drug effects
Heroin
/ adverse effects
Heroin Dependence
/ prevention & control
Male
Methamphetamine
/ adverse effects
Pyrazoles
/ pharmacology
Rats, Long-Evans
Receptor, Cannabinoid, CB1
/ antagonists & inhibitors
Reward
Rimonabant
/ adverse effects
Self Administration
AM4113
CB1 inverse agonist
CB1 neutral antagonist
CB1 receptors
SR141716A
aversion
brain-stimulation reward
depression
drug reward
self-administration
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
21
01
2018
accepted:
31
05
2018
pubmed:
4
7
2018
medline:
14
6
2019
entrez:
4
7
2018
Statut:
ppublish
Résumé
Cannabinoid CB
Identifiants
pubmed: 29967454
doi: 10.1038/s41401-018-0059-x
pii: 10.1038/s41401-018-0059-x
pmc: PMC6460369
doi:
Substances chimiques
AM4113
0
Cannabinoid Receptor Antagonists
0
Pyrazoles
0
Receptor, Cannabinoid, CB1
0
Methamphetamine
44RAL3456C
Heroin
70D95007SX
Cocaine
I5Y540LHVR
Rimonabant
RML78EN3XE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-373Subventions
Organisme : NIDA NIH HHS
ID : K02 DA000389
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 DA000389
Pays : United States
Références
Brady JE, Li G. Prevalence of alcohol and other drugs in fatally injured drivers. Addiction. 2013;108:104–14.
pubmed: 22725100
Naim-Feil J, Zangen A. Addiction. Handb Clin Neurol. 2013;116:613–30.
pubmed: 24112928
Jing L, Qiu Y, Zhang Y, Li JX. Effects of the cannabinoid CB(1) receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 2014;143:251–6.
pubmed: 25169627
pmcid: 4161648
Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6:24–30.
pubmed: 24006213
Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB(2) receptors modulate cocaine’s actions in mice. Nat Neurosci. 2011;14:1160–6.
pubmed: 21785434
pmcid: 21785434
Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. The role of CB
pubmed: 18482432
Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. Cannabinoid CB
pubmed: 25368177
pmcid: 25368177
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932–6.
pubmed: 2308954
Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1992;48:655–68.
pubmed: 1376455
Chen J, Paredes W, Lowinson JH, Gardner EL. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol. 1990;190:259–62.
pubmed: 1963849
Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048–50.
pubmed: 9197269
Oleson EB, Cheer JF. A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med. 2012;2: pii:a012229.
Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology. 2005;48:1105–16.
pubmed: 15878779
Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology. 2009;205:171–4.
pubmed: 19300982
pmcid: 2695840
Gamaleddin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR, et al. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front Psychiatry. 2015;6:41.
pubmed: 25859226
pmcid: 4373509
Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005;312:875–83.
pubmed: 15525797
Xi ZX, Spiller K, Pak AC, Gilbert J, Dillon C, Li X, et al. Cannabinoid CB1 receptor antagonists attenuate cocaine’s rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology. 2008;33:1735–45.
pubmed: 17728698
Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21:5344–50.
pubmed: 11438610
pmcid: 6762870
Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology. 2006;31:804–13.
pubmed: 16123766
Caille S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci. 2003;18:3145–9.
pubmed: 14656311
Navarro M, Carrera MR, Del Arco I, Trigo JM, Koob GF, Rodríguez de Fonseca F. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur J Pharmacol. 2004;501:235–7.
pubmed: 15464083
Schindler CW, Panlilio LV, Gilman JP, Justinova Z, Vemuri VK, Makriyannis A, et al. Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. Eur J Pharmacol. 2010;633:44–9.
pubmed: 20153314
pmcid: 2974174
Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev. 2011;16:CD005353.
De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology. 2003;168:164–9.
pubmed: 12669182
Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology. 1998;135:324–32.
pubmed: 9539255
De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2001;7:1151–4.
pubmed: 11590440
Ward SJ, Rosenberg M, Dykstra LA, Walker EA. The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend. 2009;105:248–55.
pubmed: 19679410
pmcid: 2763982
Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci. 2005;77:2339–50.
pubmed: 15935395
Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Liu J, Harvey-White J, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol. 2005;289:H533–41.
pubmed: 15821037
pmcid: 2225481
Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104:266–76.
pubmed: 19149823
Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.
Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep. 2009;61:217–24.
pubmed: 19443932
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–97.
pubmed: 15836887
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–75.
Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2185–93.
pubmed: 17959701
Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond). 2010;34:1243–54.
Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2008;33:946–55.
pubmed: 17581535
Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav. 2009;91:303–6.
pubmed: 18703081
Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, et al. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther. 2003;306:363–70.
pubmed: 12663689
Seltzman HH, Maitra R, Bortoff K, Henson J, Reggio PH, Wesley D, et al. Metabolic profiling of CB1 neutral antagonists. Methods Enzymol. 2017;593:199–215.
pubmed: 28750803
pmcid: 5802864
Pavon FJ, Bilbao A, Hernández-Folgado L, Cippitelli A, Jagerovic N, Abellán G, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Neuropharmacology. 2006;51:358–66.
pubmed: 16750544
Järbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav. 2008;91:84–90.
pubmed: 18640150
pmcid: 2630887
Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, et al. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther. 2013;344:561–7.
pubmed: 23287700
pmcid: 3583508
Wills KL, Vemuri K, Kalmar A, Lee A, Limebeer CL, Makriyannis A, et al. CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. Psychopharmacology. 2014;231:4291–300.
pubmed: 24770676
pmcid: 4209202
Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, et al. Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology. 2017;131:200–8.
pubmed: 29109060
pmcid: 5820178
Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:pii:pyw068.
Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J, et al. Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. Neuropsychopharmacology. 2016;41:2283–93.
pubmed: 26888056
pmcid: 4946059
Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–74.
pubmed: 25581144
Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry. 2011;16:974–86.
pubmed: 21519339
pmcid: 3192324
Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, et al. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil. 2010;22:787–96, e223.
pubmed: 20180825
pmcid: 2943391
Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81:263–84.
pubmed: 15936806
Xi ZX, Gilbert JG, Peng XQ, Pak AC, Li X, Gardner EL. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci. 2006;26:8531–6.
pubmed: 16914679
pmcid: 6674340
O’Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther. 2005;108:18–58.
pubmed: 16183393
Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther. 2003;306:93–102.
pubmed: 12660305
Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology. 2005;48:1097–104.
pubmed: 15910886
Alvarez-Jaimes L, Polis I, Parsons LH. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology. 2008;33:2483–93.
pubmed: 18059440
Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav. 2005;81:387–95.
pubmed: 15935455
Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology. 2008;54:438–44.
pubmed: 18054052
Budzynska B, Kruk M, Biala G. Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep. 2009;61:304–10.
pubmed: 19443943
Simonnet A, Cador M, Caille S. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict Biol. 2013;18:930–6.
pubmed: 22784230
Filip M, Gołda A, Zaniewska M, McCreary AC, Nowak E, Kolasiewicz W, et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep. 2006;58:806–19.
pubmed: 17220538
Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol. 2005;15:31–7.
pubmed: 15572271
Vinklerova J, Novakova J, Sulcova A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol. 2002;16:139–43.
pubmed: 12095072
Anggadiredja K, akamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology. 2004;29:1470–8.
pubmed: 15085091
Hiranita T, Nawata Y, Sakimura K, Yamamoto T. Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology. 2008;55:1300–6.
pubmed: 18782581
Boctor SY, Martinez JL Jr., Koek W, France CP. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. Eur J Pharmacol. 2007;571:39–43.
pubmed: 17628534
pmcid: 2148070
Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci. 1996;19:319–40.
pubmed: 8833446
Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, Malanga CJ. Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin Exp Res. 2010;34:81–9.
pubmed: 19860803
Paxinos G & Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press.